Compare DTST & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTST | NXL |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | 55 | 7 |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.3M |
| IPO Year | N/A | N/A |
| Metric | DTST | NXL |
|---|---|---|
| Price | $3.93 | $0.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 9.8K | ★ 417.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $0.37 |
| 52 Week High | $5.44 | $2.57 |
| Indicator | DTST | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 39.81 |
| Support Level | $3.74 | $0.37 |
| Resistance Level | $4.37 | $0.62 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 32.26 | 31.54 |
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.